For more information about clinical trials for anti-HIV treatments currently enrolling, see the clinical trials page Drugs for treating HIV .
Protease inhibitors are a new class of anti-HIV drugs.
They work by blocking a part of HIV called protease. When protease is blocked, HIV makes copies of itself that can't infect new cells. The current recommended dosage is 600 mg, three times a day. People taking AZT and ddC had an average increase of 72 T4 cells. The average T4 cell count of people in the study was 160-180.